REPURPOSING OF AN APPROVED DRUG SPECIFIC FOR VARIOUS NEUROLOGICAL CONDITIONS

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury.

  ASX ANNOUNCEMENTS

  PRESENTATION


5 July 2019 – Invex Therapeutics – Repurposing An Approved Drug

  SUBSCRIBE TO UPDATES

  MEDIA

  PARTNERS

  CONTACT INFORMATION

Address
Level 1, 38 Rowland St

Subiaco Perth WA 6008

Phone

+61 (08) 6382 0137

ACN 632145334

Email

info@invextherapeutics.com

Disclaimer. Copyright © Invex Therapeutics. All rights reserved. Site developed by NFIC Services.